Doctor discusses a recent study about dementia.

Tresa Mcneal, MD, at Baylor Scott & White Health, discusses a recent study about dementia. What You Need to Know: Dementia affects thinking, memory and social ability. Stroke can cause dementia. Dementia risks increase for those who are sedentary. Reduce…

Dr. Claudia Padilla discusses Alzheimer’s and a new treatment.

Claudia Padilla, MD, at Baylor Scott & White Health, discusses Alzheimer’s and a new treatment. What You Need to Know: Alzheimer’s disease is a type of dementia. The most common sign is short-term memory loss. New medication targets the protein…

IU scientists part of NIH-funded national consortium focused on improving Alzheimer’s disease diagnoses

Researchers at Indiana University School of Medicine will play key roles in a national consortium led by Wake Forest University School of Medicine to study the use, interpretation and implementation of biomarkers to diagnose Alzheimer’s disease. The multi-institution effort is funded by a five-year, $9 million grant from the National Institute on Aging, part of the National Institutes of Health, that will establish the Alzheimer’s Diagnosis in Older Adults with Chronic Conditions (ADACC) Network.

Corewell Health neuroscientist leads research to tackle disparate growth of Alzheimer’s among Black Americans

To address the growing disparity and identify multi-level risk factors impacting the higher prevalence of Alzheimer’s disease among middle-aged and older Black adults, Corewell Health neuroscientist Stewart Graham, Ph.D., in collaboration with researchers from Hampton University, Johns Hopkins and Clemson are spearheading a first-of-its-kind, five-year, $4.8 million research project.

Cerebral amyloid angiopathy, seizures, and epilepsy: Dr. Brin Freund

Sixty percent of patients with dementia on autopsy studies have cerebral amyloid angiopathy (CAA) pathology. This episode discusses the relationship between CAA and epilepsy through the lens of a recent publication. Dr. Alina Ivaniuk talks with Dr. Brin Freund.

Dr. Liana Apostolova is available to comment on new results of a phase III clinical trial of Donanemab, an Alzheimer’s disease medication for patients with early symptoms of the disease.

Liana Apostolova, MD is the associate dean of Alzheimer’s disease research at Indiana University School of Medicine. Dr. Apostolova and others presented results of the phase 3 clinical trial of Donanemab at the Alzheimer’s Association International Conference. The study, also published…

Altered gut bacteria may be early sign of Alzheimer’s disease

Alzheimer’s disease causes changes to the brain that begin two decades or more before symptoms appear. A study by researchers at Washington University School of Medicine in St. Louis reveals that the bacteria that live in the gut also change before Alzheimer’s symptoms arise, a discovery that could lead to diagnostics or treatments for Alzheimer’s disease that target the gut microbiome.

Research Group Calls for Consensus, Collaboration to Improve Understanding of how Infections Drive Alzheimer’s

A research consortium, including a Philadelphia College of Osteopathic Medicine neuroscientist and his research coordinator, are calling for a consensus on how scientists identify and evaluate how infections contribute to or cause cognitive impairment and dementias, including Alzheimer’s disease.

Degrading modified proteins could treat Alzheimer’s, other ‘undruggable’ diseases

A new technique that targets and breaks apart certain proteins — rather than just interfering with them — may offer a pathway toward treatment of Alzheimer’s disease. Researchers reporting in ACS Central Science have designed a compound that breaks down a protein closely associated with the disease.

Gut bacteria affect brain health, mouse study shows

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The study, by researchers at Washington University School of Medicine in St. Louis, indicates that gut bacteria produce compounds that influence the behavior of immune cells, including ones in the brain that can cause neurodegeneration. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.

Sanders-Brown director receives funding to advance work on potential drug

Linda J. Van Eldik, Ph.D., director of the University of Kentucky Sanders-Brown Center on Aging, is part of a $1.5 million grant to help further research into a possible treatment for Alzheimer’s disease. A four-year grant from the National Institute on Aging of the National Institutes of Health to Northwestern University includes a $611,676 subaward to UK. Van Eldik, the Dr. E. Vernon Smith and Eloise C. Smith Alzheimer’s Research Endowed Chair, serves as principal investigator on UK’s award.

UK HealthCare, Community Leaders Celebrate Opening of New Sanders-Brown Clinic

Today (July 25), UK HealthCare and community leaders celebrated the full opening of the Sanders-Brown Memory Clinic at Turfland. The new, larger clinic replaces the former Sanders-Brown facilities along North Broadway in Lexington.

The world looks to The University of Kentucky’s Sanders-Brown Center on Aging for answers to the mysteries of dementia, and the elderly rely on them for help in charting their path to a healthy and vigorous senior lifestyle. After outgrowing their old space, leaders at UK decided it was time that Sanders-Brown’s home for clinical research and patient care reflects their reputation — building them a new home on UK HealthCare’s Turfland Campus.

Science Snapshots: COVID-19, power outages, Alzheimer’s disease, and optical antennas

March Science Snapshots from Berkeley Lab

Nanoparticles Help Untangle Alzheimer’s Disease Amyloid Beta Plaques

ROCKVILLE, MD – Scientists are still a long way from being able to treat Alzheimer’s Disease, in part because the protein aggregates that can become brain plaques, a hallmark of the disease, are hard to study.

Nobody finds the Alzheimer’s Germ in $1 Million Challenge, but eight researchers split $200K, says Dr. Leslie Norins of Alzheimer’s Germ Quest

There is now keen interest in deeper investigation of infectious agents as the trigger of Alzheimer’s disease

Alzheimer’s Association again endorses Biogen drug despite mystery data analysis and financial conflict of interest, says Dr. Leslie Norins of Alzheimer’s Germ Quest

Although an expert FDA panel voted ten to one to withhold approval for a Biogen anti-Alzheimer’s drug candidate, the Alzheimer’s Association endorsed the compound. Serious questions have been raised about why, including conflict of interest.

University of Kentucky’s Sanders-Brown Center on Aging Facilitates First Participant in Worldwide Drug Study

Researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study. This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping this study finds that BAN2401 does just that and will ultimately help prevent Alzheimer’s disease.

Alzheimer’s study shows promise in protecting brain from tau

In the search for an Alzheimer’s cure, the scientific community has focused on drugs to lessen the buildup of amyloid protein in the brain. But new research published today in Science Translational Medicine finds that targeting tau pathology shows promise.The discovery came by looking at what could make worms resistant to pathological tau protein. That’s when researchers discovered the role of the MSUT2 gene. The latest study applied to mice as well. And held true in autopsy samples of Alzheimer’s patients.

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.